Erythrocytic metabolism of ATLX-0199: An agent that increases minute ventilation.

Both L- and D-isomers of S-nitrosocysteine (CSNO) can bind to the intracellular domain of voltage-gated potassium channels in vitro. CSNO binding inhibits these channels in the carotid body, leading to increased minute ventilation in vivo. However, only the l -isomer is active in vivo because it requires the l -amino acid transporter (LAT) for transmembrane transport. In rodents and dogs, the esterified D-CSNO precursor— d -cystine dimethyl ester (ATLX-0199)—overcomes opioid- and benzodiazepine-induced respiratory depression while maintaining analgesia. Although ATLX-0199 can enter cells independently of LAT because it is an ester, its stability in plasma is limited by the presence of esterases. Here, we hypothesized that the drug could be sequestered in erythrocytes to avoid de-esterification in circulation. We developed a liquid chromatography-mass spectrometry method for detecting ATLX-0199 and characterized a new metabolite, S-nitroso- d -cysteine monomethyl ester (DNOCE), which is also a D-CSNO precursor. We found that both ATLX-0199 and DNOCE readily enter erythrocytes and neurons and remain stable over 20 min; thus ATLX-0199 can enter cells where the ester is stable, but the thiol is reduced. Depending on hemoglobin conformation, the reduced ester can be S-nitrosylated and enter carotid body neurons, where it then increases minute ventilation. These data may help explain the paradox that ATLX-0199, a dimethyl ester, can avoid de-esterification in plasma and exert its effects at the level of the carotid body. • S-nitroso- d -cysteine monomethyl ester is a novel compound that is readily synthesized. • ATLX-0199 and its breakdown products diffuse into erythrocytes and neurons, and are stable over the course of 20 min. • Diffusion into erythrocytes suggest a potential mechanism ATLX-0199 avoids degradation by esterases in the plasma. [ABSTRACT FROM AUTHOR]